Welcome to our dedicated page for Daxor news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor stock.
Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor (Nasdaq: DXR) announced that CEO and President Michael Feldschuh will participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 on March 10–11, 2026.
Mr. Feldschuh will deliver a 30-minute presentation on March 10 at 2:00 PM ET and hold virtual one-on-one investor meetings on March 11. A live webcast is available at the conference webcast page and investors can request meetings via the conference website.
Daxor Corporation (Nasdaq: DXR) reported a transformative 2025 with FDA 510(k) clearance in August for a next‑generation portable Blood Volume Analyzer, unaudited operating revenue up 45% YoY, year‑end net assets of $45.89M ($9.07/share), and a post‑year $9.0M registered direct offering in January 2026.
The operating division narrowed losses to $268,598 in 2025 while investing in R&D, commercialization, and production to scale placements and sales.
Daxor (Nasdaq: DXR) reported fiscal 2025 results with operating revenue up 45% YoY and total net assets of $45,887,266 as of December 31, 2025. Net Asset Value per share rose to $9.07 (a $1.82 increase). The company received FDA 510(k) clearance in August 2025 for a next‑generation portable Blood Volume Analyzer and closed a $9.0 million registered direct offering in January 2026 at $11.75 per share to fund commercialization and expansion.
Daxor (Nasdaq: DXR) launched a BVA diagnostic program in Southern Middle Tennessee, expanding its outpatient cardiology presence on Feb. 24, 2026. The program uses the Tennessee-based ezBVA Lab to deliver comprehensive blood volume metrics with a 24-hour turnaround and claims 98% accuracy.
According to the company, the service integrates into outpatient workflows with existing reimbursement codes and requires zero capital investment for the facility.
Daxor (NASDAQ: DXR) announced it intends to change its primary reporting framework from the Investment Company Act to the Securities Exchange Act, reflecting its shift to an operating medical diagnostics business focused on Blood Volume Analysis (BVA). The company cited customer growth, revenue increases, and FDA clearance of its next-generation analyzer. Daxor expects to complete regulatory steps by the end of Q2, subject to required filings and approvals, and said Exchange Act reporting will provide standardized GAAP disclosures and improved investor comparability.
Daxor (NasdaqCM: DXR) entered a definitive agreement for a registered direct offering of 765,958 shares at $11.75 per share, expected to close on or about January 26, 2026. Gross proceeds are expected to be approximately $9 million before placement agent fees and offering expenses. The company intends to use net proceeds for general corporate purposes, including working capital. Lake Street Capital Markets is the exclusive placement agent. The related Form N-2 registration was declared effective on January 20, 2026. The offering will be made only by prospectus supplement and accompanying prospectus and will be filed with the SEC.
Daxor (Nasdaq: DXR) announced on November 25, 2025 that its Blood Volume Analysis (BVA) platform expanded into three new facilities, combining on-site analyzer deployments with its CLIA-certified ezBVA Lab Service for next-day results. New adoptions include an Upper Midwest integrated health system using ezBVA for high-volume cardiology and heart failure diagnostics, an Ohio academic medical center using ezBVA for outpatient advanced heart failure management, and a Southwest cardiology group practice that onboarded the new on-site BVA analyzer for immediate in-office assessments. Management said the dual on-site plus lab approach is driving accelerating market traction and anticipated continued sales momentum among clinicians focused on precision fluid management.
Daxor (Nasdaq: DXR) announced that President and CEO Michael Feldschuh will meet institutional investors at the Maxim Growth Summit on October 22–23, 2025 at the Hard Rock Hotel in New York City.
Mr. Feldschuh will be available for one-on-one investor meetings and will meet with senior Maxim analysts; participation in the summit is by invitation. Institutional investors seeking meetings are directed to contact Bret Shapiro, COO – Head of Capital Markets, COREIR, via phone (561)-479-8566 or email brets@coreir.com. For the full summit agenda visit www.maximgrp.com/2025-growth-summit.
Daxor (NASDAQ: DXR) will exhibit at the MedAxiom Cardiovascular Transforum Fall'25 at the JW Marriott Austin from October 16–18, 2025. The company plans to debut its next‑generation BVA diagnostic system and demonstrate how the technology addresses hospital readmissions and resource optimization for cardiovascular providers. CEO Michael Feldschuh said the launch is expected to accelerate sales momentum and support wider commercial adoption by connecting with cardiovascular innovators.
The appearance positions Daxor to showcase clinical and operational benefits to health systems and potential customers attending the conference in Austin, TX.
Daxor Corporation (Nasdaq: DXR) unveiled its newly FDA-cleared next-generation Blood Volume Analysis (BVA) analyzer at the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The new system features enhanced ease of use, speed, and over 95% accuracy.
Three pivotal studies from leading institutions validated BVA technology's effectiveness: Banner University Medical Center reported zero unplanned hospital admissions for optimally managed patients, Wellstar Health System demonstrated improved LVAD outcomes with increased survival rates and reduced readmissions, and Geisinger Medical Center confirmed BVA's utility in diagnosing Cardiac Amyloidosis.